ImmunityBio, Inc. (IBRX) stock analysis

In our weekly check, ImmunityBio, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 11.

About ImmunityBio, Inc.

ImmunityBio, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as IBRX.

What our checks show for IBRX

Red flags

Warning signs

Strengths

Similar companies

CAI · BLTE · LGND · CGON · MIRM · ARWR

Questions

What grade does ImmunityBio, Inc. (IBRX) have?

In our weekly check, ImmunityBio, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 9 pass, warnings: 2, red flags: 11. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of IBRX stock?

This week's biggest flags for ImmunityBio, Inc.: High debt, Weak interest cover, Gross margin falling. In total 13 of 22 checks show a warning or a red flag.

What does ImmunityBio, Inc. do?

ImmunityBio, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as IBRX.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis